NeuroSense Therapeutics (NRSN) investor relations material

Corporate highlights and leadership

• Achieved significant positive results in a placebo-controlled phase 2b study for ALS, with PrimeC slowing disease progression by ~33% over 18 months (p=0.007).

• Patent protection for PrimeC extends until 2042, covering formulation, method, and combination.

• Orphan drug designation and expedited regulatory pathway support development.

• Leadership team includes experienced executives and a renowned scientific advisory board with global ALS experts.

ALS market opportunity and unmet need

• ALS is a rapidly progressing, terminal disease with an average survival of 2–5 years and limited treatment options.

• Over 200,000 ALS patients worldwide, with >30,000 in the US and Canada, and a projected 24% growth in patients by 2040 in the US and EU.

• Annual market opportunity for ALS therapies exceeds $1B, with current drug prices around $160,000/year.

PrimeC mechanism and clinical rationale

• PrimeC is a patented, fixed-dose combination of celecoxib and ciprofloxacin, designed for synchronized release and multi-targeted action.

• Targets neuroinflammation, iron metabolism dysregulation, and miRNA regulation, with demonstrated synergy not seen with either agent alone.

• Preclinical and clinical studies show PrimeC reduces neuroinflammation, improves iron metabolism, and modulates key ALS-related miRNAs.